India based pharmaceutical company, Lupin Limited, announced on Tuesday that it has received approval for its Meloxicam Capsules, 5mg and 10mg, from the United States Food and Drug Administration (US FDA), to market as a generic equivalent of Vivlodex(R) Capsules, 5mg and 1 mg, from Zyla Life Sciences US Inc.
The product will be manufactured at Lupin's Aurangabad facility, India, and is expected to be launched shortly. Meloxicam Capsules, 5mg and 10mg, are indicated for management of osteoarthritis (OA) pain.
Meloxicam Capsules (RLD: Vivlodex(R)) had annual sales of approximately USD14m in the US (IQVIA MAT March 2020).
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling